IP Library › Assignment 071079/0653
Patent Assignment
Reel/Frame 071079/0653

Corrective Assignment to Correct the Erroneous Reference to Application Numbers 10847252, 10847253 and 11183286 to Instead Reflect the Patent Numbers Listed in the Recorded Assignment Document Previously Recorded on Reel 70760 Frame 165. Assignor(S) Hereby Confirms the the Assignment.

Recorded: 2025-04-25 Pages: 30
Assignor
GRITSTONE BIO, INC.
Executed: 2024-12-30
Assignee
SEATTLE PROJECT CORP.
C/O INCORPORATING SERVICES, LTD., 3500 SOUTH DUPONT HIGHWAY, DOVER, DELAWARE, 19901
Covered Properties (164)
Neoantigen Identification, Manufacture, and Use
Application: 17/101,522 →
Publication: US 2021/0166784
Neoantigen Identification, Manufacture, and Use
Application: 15/381,375 →
Publication: US 2017/0199961
Neoantigen Identification, Manufacture, and Use
Application: 15/466,729 →
Publication: US 2017/0212984
Neoantigen Identification, Manufacture, and Use
Application: 16/128,421 →
Publication: US 2019/0034585
Neoantigen Identification, Manufacture, and Use
Application: 62/268,333 →
Neoantigen Identification, Manufacture, and Use
Application: 62/317,823 →
Neoantigen Identification, Manufacture, and Use
Application: 62/379,986 →
Neoantigen Identification, Manufacture, and Use
Application: 62/394,074 →
Neoantigen Identification, Manufacture, and Use
Application: 62/425,995 →
Neoantigen Identification, Manufacture, and Use
Application: 18/431,595 →
Publication: US 2025/0316334
Neoantigen Identification, Manufacture, and Use
Application: 62/487,469 →
Neoantigen Identification, Manufacture, and Use
Application: 16/606,577 →
Publication: US 2021/0113673
Alphavirus Neoantigen Vectors
Application: 62/503,283 →
Alphavirus Neoantigen Vectors
Application: 62/523,201 →
Alphavirus Neoantigen Vectors
Application: 62/590,163 →
Alphavirus Neoantigen Vectors
Application: 16/612,352 →
Publication: US 2020/0197500
Alphavirus Antigen Vectors
Application: 17/693,029 →
Publication: US 2022/0226453
Alphavirus Neoantigen Vectors
Application: 18/045,812 →
Publication: US 2024/0024445
Viral Delivery of Neoantigens
Application: 62/435,266 →
Viral Delivery of Neoantigens
Application: 62/503,196 →
Viral Delivery of Neoantigens
Application: 62/425,996 →
Viral Delivery of Neoantigens
Application: 62/523,212 →
Viral Delivery of Neoantigens
Application: 16/463,787 →
Publication: US 2020/0010849
Viral Delivery of Neoantigens
Application: 18/152,699 →
Publication: US 2024/0067985
Antigen-Binding Proteins Targeting Shared Antigens
Application: 18/065,223 →
Publication: US 2023/0382997
Antigen-Binding Proteins Targeting Shared Antigens
Application: 16/639,073 →
Publication: US 2021/0147550
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/581,368 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/547,146 →
Reducing Junction Epitope Presentation for Neoantigens
Application: 18/504,497 →
Publication: US 2024/0361335
Neoantigen identification, manufacture, and use
Application: 62/590,045 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 16/958,615 →
Publication: US 2021/0061914
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/611,403 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/756,508 →
Immune Checkpoint Inhibitor Co-expression Vectors
Application: 62/675,624 →
Immune Checkpoint Inhibitor Co-Expression Vectors
Application: 17/058,113 →
Publication: US 2021/0213122
Immune Checkpoint Inhibitor Co-Expression Vectors
Application: 18/404,681 →
Publication: US 2025/0025544
Shared Antigens
Application: 17/058,128 →
Publication: US 2021/0196806
Shared Antigen Compositions and Related Methods
Application: 62/675,649 →
Shared Neoantigens
Application: 62/675,559 →
Alphavirus Neoantigen Vectors and Interferon Inhibitors
Application: 62/756,980 →
Alphavirus Neoantigen Vectors and Interferon Inhibitors
Application: 17/291,984 →
Publication: US 2022/0125919
Identification of Neoantigens with Mhc Class Ii Model
Application: 17/436,367 →
Publication: US 2022/0154281
Modified Adenoviruses
Application: 62/854,865 →
Modified Adenoviruses
Application: 17/538,716 →
Publication: US 2022/0090138
Modified Adenoviruses
Application: 18/150,141 →
Publication: US 2023/0407332
Hiv Antigens and Mhc Complexes
Application: 17/817,312 →
Publication: US 2023/0128001
Hiv Antigens and Mhc Complexes
Application: 17/564,920 →
Publication: US 2022/0265812
HIV Antigens and MHC Complexes
Application: 63/029,981 →
HIV Antigens and MHC Complexes
Application: 62/869,877 →
Neoantigen Identification, Manufacture, and Use
Application: 16/619,652 →
Publication: US 2020/0105377
Neoantigen Identification, Manufacture, and Use
Application: 62/517,786 →
Neoantigen Identification for T-Cell Therapy
Application: 16/644,934 →
Publication: US 2020/0363414
Neoantigen Identification, Manufacture, and Use
Application: 62/644,191 →
Neoantigen identification, manufacture, and use
Application: 62/579,734 →
Neoantigen Identification, Manufacture, and Use
Application: 62/554,286 →
Neoantigen Identification, Manufacture, and Use
Application: 62/703,197 →
Neoantigen Identification Using Hotspots
Application: 17/581,788 →
Publication: US 2022/0148681
Neoantigen Identification, Manufacture, and Use
Application: 62/570,569 →
Neoantigen Identification with Pan-Allele Models
Application: 16/975,823 →
Publication: US 2020/0411135
Neoantigen Identification, Manufacture, and Use
Application: 62/636,061 →
Antigen-Binding Proteins Targeting Shared Neoantigens
Application: 17/744,354 →
Publication: US 2023/0041030
Antigen-Binding Proteins Targeting Shared Neoantigens
Application: 63/030,774 →
Antigen-Binding Proteins Targeting Shared Neoantigens
Application: 62/936,303 →
Antigen Binding Proteins Targeting Shared Neoantigens
Application: 62/930,374 →
Shared Neoantigen Vaccines
Application: 17/736,738 →
Publication: US 2023/0020089
Neoantigen Vaccine Therapy
Application: 63/051,227 →
Neoantigen Vaccines
Application: 62/959,798 →
Neoantigen Vaccines
Application: 62/946,956 →
Shared Neoantigen Vaccines
Application: 62/930,460 →
Cell-Free Dna Monitoring
Application: 17/861,088 →
Publication: US 2023/0104840
Cell-Free Dna Monitoring
Application: 62/959,805 →
Durable Vaccination
Application: 62/946,947 →
Durable Vaccination
Application: 17/838,114 →
Publication: US 2023/0047979
Antigen-Encoding Cassettes
Application: 18/048,403 →
Publication: US 2023/0310563
Antigen-Encoding Cassettes
Application: 63/013,466 →
Capping Compounds, Compositions and Methods of Use Thereof
Application: 63/013,456 →
Capping Compounds, Compositions and Methods of Use Thereof
Application: 63/020,473 →
Capping Compounds, Compositions and Methods of Use Thereof
Application: 18/048,407 →
Publication: US 2023/0303614
Infectious Disease Antigens and Vaccines
Application: 17/937,751 →
Publication: US 2024/0050550
Infectious Disease Antigens and Vaccines
Application: 63/005,160 →
Sars-Cov-2 Vaccines
Application: 18/057,171 →
Publication: US 2023/0330215
Sars-Cov-2 Vaccines
Application: 63/139,292 →
Sars-Cov-2 Vaccines
Application: 63/047,789 →
Sars-Cov-2 Vaccines
Application: 63/027,283 →
Multiepitope Vaccine Cassettes
Application: 18/458,062 →
Publication: US 2024/0285739
Multiepitope Vaccine Cassettes
Application: 63/062,268 →
Homologous Adenoviral Vaccination
Application: 63/121,164 →
Homologous Adenoviral Vaccination
Application: 18/272,087 →
Publication: US 2024/0093235
Compositions and Methods of Use Thereof
Application: 63/121,603 →
Compositions and Methods of Use Thereof
Application: 18/255,539 →
Publication: US 2024/0033334
Modified Alphavirus Vectors
Application: 63/139,297 →
Sars-Cov-2 Vaccines
Application: 18/658,552 →
Publication: US 2025/0121052
Pancoronavirus Vaccines
Application: 18/622,497 →
Publication: US 2024/0238412
Pancoronavirus Vaccines
Application: 63/374,664 →
Pan-Coronavirus Vaccines
Application: 63/251,441 →
Neoantigen Adjuvant and Maintenance Therapy
Application: 18/607,027 →
Publication: US 2024/0216501
Neoantigen Adjuvant and Maintenance Therapy
Application: 63/320,685 →
Neoantigen Adjuvant and Maintenance Therapy
Application: 63/281,027 →
Neoantigen Adjuvant Therapy
Application: 63/245,663 →
Kras-Neoantigen Therapies
Application: 18/607,061 →
Publication: US 2024/0238397
Self-Amplifying Rna Compositions and Methods of Use Thereof
Application: 63/277,116 →
Low-Dose Neoantigen Vaccine Therapy
Application: 18/891,398 →
Publication: US 2025/0255946
Compositions and Methods of Use Thereof
Application: 63/350,345 →
Antigen Predictions for Infectious Disease-Derived Epitopes
Application: 18/908,082 →
Publication: US 2025/0273288
Antigen Predictions for Infectious Disease-Derived Epitopes
Application: 63/329,259 →
Selection of T Cell Receptors
Application: 17/433,817 →
Publication: US 2022/0155321
Selection of T Cell Receptors
Application: 62/812,572 →
Egfr Vaccine Cassettes
Application: 63/392,072 →
Cta Vaccine Cassettes
Application: 63/370,364 →
Compositions and Methods of Use Thereof
Application: 63/429,897 →
Hybrid Panel Cell-Free Dna Monitoring
Application: 63/381,747 →
Epitope Prediction via a Learned Genotype Network Across Class Ii Mhc Alleles
Application: 63/489,888 →
KRAS MHC Class II Compositions and Methods
Application: 63/489,944 →
Epitope Prediction via a Learned Genotype Network Across Class Ii Mhc Alleles
Application: 63/611,654 →
Personalized Cancer Vaccines and Methods of Use
Application: 63/570,640 →
Title Not Available
Application: 63/691,663 →
Neoantigen Identification, Manufacture, and Use
Application: 16/001,569 →
Publication: US 2019/0065675
Neoantigen identification, manufacture, and use
Application: 16/040,409 →
Publication: US 2018/0330055
Neoantigen Identification, Manufacture, and Use
Application: 17/101,518 →
Publication: US 2021/0098077
Neoantigen Identification, Manufacture, and Use
Application: 15/466,729 →
Publication: US 2017/0212984
Reducing Junction Epitope Presentation for Neoantigens
Application: 16/766,627 →
Publication: US 2021/0011026
Neoantigen Identification Using Hotspots
Application: 16/403,331 →
Publication: US 2019/0279742
Multiepitope Vaccine Cassettes
Application: 17/727,610 →
Publication: US 2022/0265797
Neoantigen Identification, Manufacture, and Use
Neoantigen Identification, Manufacture, and Use
Alphavirus Neoantigen Vectors
Viral Delivery of Neoatigens
Antigen-Binding Proteins Tatrgeting Shared Antigens
Reducing Junction Epitope Presentation for Neoantigens
Antigen-Binding Proteins Targeting Shared Antigens
Immune Checkpoint Inhibitor Co-Expression Vectors
Alphavirus Neoantigen Vectors and Interferon Inhibitors
Identification of Neoantigens with Mhc Class Ii Model
Modified Adenoviruses
Hiv Antigens and Mhc Complexes
Neoantigen Identification, Manufacture, and Use
Neoantigen Identification for T-Cell Therapy
Neoantigen Identification Using Hotspots
Neoantigen Identification with Pan-Allele Models
Antigen-Binding Proteins Targeting Shared Neoantigens
Antigen-Binding Proteins Targeting Shared Neoantigens
Neoantigen Vaccine Therapy
Cell-Free Dna Monitoring
Durable Vaccination
Antigen-Encoding Cassettes
Capping Compounds, Compositions and Methods of Use Thereof
Infectious Disease Antigens and Vaccines
Sars-Cov-2 Vaccines
Multiepitope Vaccine Cassettes
Homologous Adenoviral Vaccination
Compositions and Methods of Use Thereof
Modified Alphavirus Vectors
Pancoronavirus Vaccines
Neoantigen Adjuvant and Maintenance Therapy
Self-Amplifying Rna Compositions and Methods of Use Thereof
Compositions and Methods of Use Thereof
Antigen Predictions for Infectious Disease-Derived Epitopes
Selection of T Cell Receptors
Egfr Vaccine Cassettes
Cta Vaccine Cassettes
Compositions and Methods of Use Thereof
Combination Panel Cell-Free Dna Monitoring
Epitope Prediction via a Learned Genotype Network Across Class Ii Mhc Alleles
Shared Antigens
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 21, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SILLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 039819/0930 →
Assignment of Assignor's Interest Sep 21, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SILLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 039819/0647 →
Assignment of Assignor's Interest Sep 21, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SILLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 039819/0627 →
Corrective Assignment to Correct the Name of the Third Inventor Previously Recorded on Reel 039819 Frame 0647. Assignor(S) Hereby Confirms the Assignment. Nov 22, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 040665/0424 →
Corrective Assignment to Correct the Name of Third Inventor Previously Recorded on Reel 039819 Frame 0930. Assignor(S) Hereby Confirms the Assignment. Nov 22, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 040665/0413 →
Assignment of Assignor's Interest Dec 1, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSHY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 040485/0679 →
Corrective Assignment to Correct the Third Inventors Name Previously Recorded on Reel 039819 Frame 0627. Assignor(S) Hereby Confirms the Correct Spelling Is Brendan Bulik-Sullivan. Jan 11, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 041330/0039 →
Corrective Assignment to Correct the Fourth Inventors Name Previously Recorded on Reel 040485 Frame 0679. Assignor(S) Hereby Confirms the Correct Spelling Is Jennifer Busby. Jan 11, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 041329/0909 →
Assignment of Assignor's Interest May 20, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 042445/0268 →
Assignment of Assignor's Interest May 20, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, B; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 042445/0264 →
Assignment of Assignor's Interest May 20, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 042445/0260 →
Assignment of Assignor's Interest Aug 18, 2017
From: JOOSS, KARIN; BLAIR, WADE; YELENSKY, ROMAN; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043335/0054 →
Assignment of Assignor's Interest Aug 22, 2017
From: BLAIR, WADE; JOOSS, KARIN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043359/0306 →
Assignment of Assignor's Interest Aug 29, 2017
From: JOOSS, KARIN; BLAIR, WADE; YELENSKY, ROMAN; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043440/0492 →
Assignment of Assignor's Interest Sep 6, 2017
From: YELENSKY, ROMAN; BUSBY, MICHELE ANNE; BUSBY, JENNIFER; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043496/0772 →
Assignment of Assignor's Interest Oct 20, 2017
From: JOOSS, KARIN; WADE, BLAIR; YELENSKY, ROMAN; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043917/0791 →
Assignment of Assignor's Interest Oct 20, 2017
From: BLAIR, WADE; JOOSS, KARIN; SCALLAN, CIARAN DANIEL; GITLIN, LEONID
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043917/0610 →
Assignment of Assignor's Interest Nov 2, 2017
From: BLAIR, WADE; JOOSS, KARIN; RAPPAPORT, AMY RACHEL; SCALLAN, CIARAN DANIEL
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 044018/0141 →
Assignment of Assignor's Interest Nov 16, 2017
From: BLAIR, WADE; JOOSS, KARIN; SCALLAN, CIARAN DANIEL; GITLIN, LEONID
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 044155/0450 →
Assignment of Assignor's Interest Nov 21, 2017
From: GROTENBREG, GIJSBERT
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 044193/0897 →
Assignment of Assignor's Interest Nov 22, 2017
From: BLAIR, WADE
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 044202/0461 →
Assignment of Assignor's Interest Feb 8, 2018
From: BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 044876/0251 →
Assignment of Assignor's Interest Mar 29, 2018
From: YELENSKY, ROMAN; DETRI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 045382/0486 →
Assignment of Assignor's Interest Mar 29, 2018
From: YELENSKY, ROMAN; BUSBY, MICHELE ANNE; BUSBY, JENNIFER; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 045382/0423 →
Assignment of Assignor's Interest Apr 6, 2018
From: BLAIR, WADE; JOOSS, KARIN; RAPPAPORT, AMY RACHEL; SCALLAN, CIARAN DANIEL
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 045466/0461 →